Possible clinical effects of molecular hydrogen (H2) delivery during hemodialysis in chronic dialysis patients: Interim analysis in a 12 month observation.
Masaaki Nakayama, Noritomo Itami, Hodaka Suzuki, Hiromi Hamada, Naoyuki Osaka, Ryo Yamamoto, Kazumasa Tsunoda, Hirofumi Nakano, Kimio Watanabe, Wan-Jun Zhu, Yukio Maruyama, Hiroyuki Terawaki, Shigeru Kabayama, Ryoichi Nakazawa, Mariko Miyazaki, Sadayoshi Ito · PloS one · 2017
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 262 patients, the data indicates E-HD could have substantial clinical benefits beyond conventional HD therapy, and support the rationale to conduct clinical trials of H₂ application to HD treatment. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence fatigue-related outcomes.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 262 patients. The data indicates E-HD could have substantial clinical benefits beyond conventional HD therapy, and support the rationale to conduct clinical trials of H₂ application to HD treatment.
What the Researchers Studied
The researchers studied 262 patients. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
The data indicates E-HD could have substantial clinical benefits beyond conventional HD therapy, and support the rationale to conduct clinical trials of H₂ application to HD treatment. Recent studies have shown that molecular hydrogen (H₂) is biologically active as an anti-inflammatory agent.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence fatigue-related outcomes and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 262 patients. The reported sample size was 262. The study used a human clinical study.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.